期刊文献+

多西他赛作为一线用药治疗卵巢癌的费用效果分析

原文传递
导出
摘要 目的对多西他赛作为一线用药治疗卵巢癌进行疗效及经济学的评价,为临床有效、经济的选择化疗方案提供参考。方法回顾性调查我院2008年3月至2011年2月住院的行多西他赛/卡铂化疗、紫杉醇/卡铂化疗及紫杉醇/卡铂化疗后多西他赛巩固治疗的卵巢癌初诊患者共35例250个疗程,分析比较3组的治疗成本、疗效及毒副作用。结果多西他赛/卡铂组、紫杉醇/卡铂组及多西他赛巩固治疗组有效率分别为91.7%、100%和88.9%(P>0.05),人均住院总费用分别为(75 106±21 232)、(137 053±8 530)和(186 051±21 938)元(P<0.01)。结论多西他赛作为一线用药治疗卵巢癌疗效稳定,耐受性好,费用最低。
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第11期870-872,共3页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献17

  • 1GREENLEE R T, HILL-HARMON M B, MURRAY T, et al. Canc- er statistics, 2001 J ]. CA Cancer J Clin, 2001,51 ( 1 ) : 15-36.
  • 2COLEMAN R L. Emerging role of topotecan in front-line treatment of carcinoma of the ovary[J]. Oncologist, 2002,7(5) :46-55.
  • 3MARKMAN M, KENNEDY A, WEBSTER K,et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum [ J ]. J Clin Oncol, 2001 , 19 (7) : 1901-1905.
  • 4ROSE P G, BLESSING J A, BALL H G, et al. A phaselI study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study[ J ]. Gynecol Onco1,2003,88 (2) :130-135.
  • 5VERSCHRAEGEN C F, SITTISOMWONG T, KUDELKA A P, et al. Docetaxe! for patients with paclitaxel-resistant Mullerian carcinoma[J]. J Clin On.col, 2000,18(14) :2733-2739.
  • 6PICCART M J, GORE M, TEN BOKKEL HUININK W, et al. Docetaxel : an active new drug for treatment of advanced epithelial ovarian cancer[J]. J Natl Cancer lnst ,1995 , 87 ( 9 ) :676-681.
  • 7PFISTERER J, DU BOIS A, WAGNER U, et al. Dncetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological thmors. A phase I/II trial of the Arbeitsgemein- schaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group [ J ]. Ccynecol Oncol, 2004, 92 ( 3 ) :949-956.
  • 8VOROBIOF D A, RAPOPORT B L, CHASEN M R, et al. Phase II clinical trial of carbopaltin and docetaxel in patients with meta- static ovarian cancer: Active combination with low incidence of peripheral neuropathy[ J]. lnt J Gynecol Cancer, 2003, 13 (3) : 287-291.
  • 9DIERAS V, GUASTALLA J P, FERRERO J M, et al. A multi- center phase II study of eisplatin and docetaxel (Taxotere) in the first line treatment of advanced ovarian cancer: a GINECO study [J]. Catuer Chemother Pharmacol, 2004, 53(6): 489-495.
  • 10VSAEY P A, JAYSON G C, GORDON A, et al. Phase Ili ran- domized thial of docetaxel-carbophin versus paclitaxel-carboplatin as first line chemotherapy for ovarian carcinoma[J]. 3 Nat Canc- er Inst Cancer Institute, 2004, 96(22) : 1682-1691.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部